Fibrin sealant - Grifols

Drug Profile

Fibrin sealant - Grifols

Alternative Names: FS Grifols; Human fibrinogen / human thrombin - Grifols; VeraSeal

Latest Information Update: 05 Feb 2016

Price : $50

At a glance

  • Originator Grifols
  • Class Acute-phase proteins; Adhesives; Antifibrinolytics; Antihaemorrhagics; Blood coagulation factors; Coagulants; Serine endopeptidases
  • Mechanism of Action Fibrinogen replacements; Thrombin replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Surgical blood loss

Most Recent Events

  • 01 Dec 2015 Grifols completes a phase-III trial in Surgical blood loss in Hungary, Serbia, Russia and USA (Topical) (NCT01754480)
  • 01 Dec 2015 Grifols completes a phase-III trial in Surgical blood loss in Hungary, Serbia, Russia and USA (Topical) (NCT01662856)
  • 29 Sep 2015 Regulatory submission withdrawn for Surgical blood loss in Norway, Iceland, Liechtenstein and European Union (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top